OBJECTIVES:Clinical experience regarding the use of dedicated photon-counting breast CT (PC-BCT) for diagnosis of breast microcalcifications is scarce. This study systematically compares the detection and classification of breast microcalcifications using a dedicated breast photon-counting CT, especially designed for examining the breast, in comparison with digital breast tomosynthesis (DBT). MATERIALS AND METHODS:This is a prospective intraindividual study on women with DBT screening-detected BI-RADS-4/-5 microcalcifications who underwent PC-BCT before biopsy. PC-BCT images were reconstructed with a noninterpolated spatial resolution of 0.15 × 0.15 × 0.15 mm (reconstruction mode 1 [RM-1]) and with 0.3 × 0.3 × 0.3 mm (reconstruction mode 2 [RM-2]), plus thin-slab maximum intensity projection (MIP) reconstructions. Two radiologists independently rated the detection of microcalcifications in direct comparison with DBT on a 5-point scale. The distribution and morphology of microcalcifications were then rated according to BI-RADS. The size of the smallest discernible microcalcification particle was measured. For PC-BCT, the average glandular dose was determined by Monte Carlo simulations; for DBT, the information provided by the DBT system was used. RESULTS:Between September 2022 and July 2023, 22 participants (mean age, 61; range, 42-85 years) with microcalcifications (16 malignant; 6 benign) were included. In 2/22 with microcalcifications in the posterior region, microcalcifications were not detectable on PC-BCT, likely because they were not included in the PC-BCT volume. In the remaining 20 participants, microcalcifications were detectable. With high between-reader agreement (κ > 0.8), conspicuity of microcalcifications was rated similar for DBT and MIPs of RM-1 (mean, 4.83 ± 0.38 vs 4.86 ± 0.35) ( P = 0.66), but was significantly lower ( P < 0.05) for the remaining PC-BCT reconstructions: 2.11 ± 0.92 (RM-2), 2.64 ± 0.80 (MIPs of RM-2), and 3.50 ± 1.23 (RM-1). Identical distribution qualifiers were assigned for PC-BCT and DBT in 18/20 participants, with excellent agreement (κ = 0.91), whereas identical morphologic qualifiers were assigned in only 5/20, with poor agreement (κ = 0.44). The median size of smallest discernible microcalcification particle was 0.2 versus 0.6 versus 1.1 mm in DBT versus RM-1 versus RM-2 ( P < 0.001), likely due to blooming effects. Average glandular dose was 7.04 mGy (PC-BCT) versus 6.88 mGy (DBT) ( P = 0.67). CONCLUSIONS:PC-BCT allows reliable detection of in-breast microcalcifications as long as they are not located in the posterior part of the breast and allows assessment of their distribution, but not of their individual morphology.

Objectives Clinical experience regarding the use of dedicated photon-counting breast CT (PC-BCT) for diagnosis of breast microcalcifications is scarce. This study systematically compares the detection and classification of breast microcalcifications using a dedicated breast photon-counting CT, especially designed for examining the breast, in comparison with digital breast tomosynthesis (DBT). Materials and Methods This is a prospective intraindividual study on women with DBT screening–detected BI-RADS-4/-5 microcalcifications who underwent PC-BCT before biopsy. PC-BCT images were reconstructed with a noninterpolated spatial resolution of 0.15 × 0.15 × 0.15 mm (reconstruction mode 1 [RM-1]) and with 0.3 × 0.3 × 0.3 mm (reconstruction mode 2 [RM-2]), plus thin-slab maximum intensity projection (MIP) reconstructions. Two radiologists independently rated the detection of microcalcifications in direct comparison with DBT on a 5-point scale. The distribution and morphology of microcalcifications were then rated according to BI-RADS. The size of the smallest discernible microcalcification particle was measured. For PC-BCT, the average glandular dose was determined by Monte Carlo simulations; for DBT, the information provided by the DBT system was used. Results Between September 2022 and July 2023, 22 participants (mean age, 61; range, 42–85 years) with microcalcifications (16 malignant; 6 benign) were included. In 2/22 with microcalcifications in the posterior region, microcalcifications were not detectable on PC-BCT, likely because they were not included in the PC-BCT volume. In the remaining 20 participants, microcalcifications were detectable. With high between-reader agreement (κ > 0.8), conspicuity of microcalcifications was rated similar for DBT and MIPs of RM-1 (mean, 4.83 ± 0.38 vs 4.86 ± 0.35) (P = 0.66), but was significantly lower (P < 0.05) for the remaining PC-BCT reconstructions: 2.11 ± 0.92 (RM-2), 2.64 ± 0.80 (MIPs of RM-2), and 3.50 ± 1.23 (RM-1). Identical distribution qualifiers were assigned for PC-BCT and DBT in 18/20 participants, with excellent agreement (κ = 0.91), whereas identical morphologic qualifiers were assigned in only 5/20, with poor agreement (κ = 0.44). The median size of smallest discernible microcalcification particle was 0.2 versus 0.6 versus 1.1 mm in DBT versus RM-1 versus RM-2 (P < 0.001), likely due to blooming effects. Average glandular dose was 7.04 mGy (PC-BCT) versus 6.88 mGy (DBT) (P = 0.67). Conclusions PC-BCT allows reliable detection of in-breast microcalcifications as long as they are not located in the posterior part of the breast and allows assessment of their distribution, but not of their individual morphology.

Background Photon-counting CT (PCCT) has been shown to improve cardiovascular CT imaging in adults. Data in neonates, infants, and young children under the age of 3 years are missing. Purpose To compare image quality and radiation dose of ultrahigh-pitch PCCT with that of ultrahigh-pitch dual-source CT (DSCT) in children suspected of having congenital heart defects. Materials and Methods This is a prospective analysis of existing clinical CT studies in children suspected of having congenital heart defects who underwent contrast-enhanced PCCT or DSCT in the heart and thoracic aorta between January 2019 and October 2022. CT dose index and dose-length product were used to calculate effective radiation dose. Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were calculated by standardized region-of-interest analysis. SNR and CNR dose ratios were calculated. Visual image quality was assessed by four independent readers on a five-point scale: 5, excellent or absent; 4, good or minimal; 3, moderate; 2, limited or substantial; and 1, poor or massive. Results Contrast-enhanced PCCT (n = 30) or DSCT (n = 84) was performed in 113 children (55 female and 58 male participants; median age, 66 days [IQR, 15-270]; median height, 56 cm [IQR, 52-67]; and median weight, 4.5 kg [IQR, 3.4-7.1]). A diagnostic image quality score of at least 3 was obtained in 29 of 30 (97%) with PCCT versus 65 of 84 (77%) with DSCT. Mean overall image quality ratings were higher for PCCT versus DSCT (4.17 vs 3.16, respectively; P < .001). SNR and CNR were higher for PCCT versus DSCT with SNR (46.3 ± 16.3 vs 29.9 ± 15.3, respectively; P = .007) and CNR (62.0 ± 50.3 vs 37.2 ± 20.8, respectively; P = .001). Mean effective radiation doses were similar for PCCT and DSCT (0.50 mSv vs 0.52 mSv; P = .47). Conclusion At a similar radiation dose, PCCT offers a higher SNR and CNR and thus better cardiovascular imaging quality than DSCT in children suspected of having cardiac heart defects. © RSNA, 2023.

Background Reducing the amount of contrast agent needed for contrast-enhanced breast MRI is desirable. Purpose To investigate if generative adversarial networks (GANs) can recover contrast-enhanced breast MRI scans from unenhanced images and virtual low-contrast-enhanced images. Materials and Methods In this retrospective study of breast MRI performed from January 2010 to December 2019, simulated low-contrast images were produced by adding virtual noise to the existing contrast-enhanced images. GANs were then trained to recover the contrast-enhanced images from the simulated low-contrast images (approach A) or from the unenhanced T1- and T2-weighted images (approach B). Two experienced radiologists were tasked with distinguishing between real and synthesized contrast-enhanced images using both approaches. Image appearance and conspicuity of enhancing lesions on the real versus synthesized contrast-enhanced images were independently compared and rated on a five-point Likert scale. P values were calculated by using bootstrapping. Results A total of 9751 breast MRI examinations from 5086 patients (mean age, 56 years ± 10 [SD]) were included. Readers who were blinded to the nature of the images could not distinguish real from synthetic contrast-enhanced images (average accuracy of differentiation: approach A, 52 of 100; approach B, 61 of 100). The test set included images with and without enhancing lesions (29 enhancing masses and 21 nonmass enhancement; 50 total). When readers who were not blinded compared the appearance of the real versus synthetic contrast-enhanced images side by side, approach A image ratings were significantly higher than those of approach B (mean rating, 4.6 ± 0.1 vs 3.0 ± 0.2; P < .001), with the noninferiority margin met by synthetic images from approach A (P < .001) but not B (P > .99). Conclusion Generative adversarial networks may be useful to enable breast MRI with reduced contrast agent dose. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Bahl in this issue.

Zielsetzung Erste Erfahrungen zur Beurteilbarkeit von Mikroverkalkungen (MC) unter Verwendung eines dedizierten Photon-Counting-Brust-CTs (PC-BCT) im intra-individuellen Vergleich zur Digitalen Tomosynthese (DBT).

Zielsetzung Die Kontrastmittel (KM)-unterstützte MRT der Mamma ist die sensitivste Methode zur Brustkrebsdetektion. Obwohl durch exzellente Verträglichkeit charakterisiert, wäre es dennoch erstrebenswert, die KM-Dosis zu reduzieren bei Kompensation durch Methoden der Bildnachverarbeitung. Ziel dieser Studie war, ein Generative Adversarial Network (GAN) zur Synthese von Subtraktionsbildern zu nutzen und die Bildqualität durch Mamma-Radiologen zu bewerten.

Levonorgestrel-releasing intrauterine contraceptive devices (LNG-IUDs) are designed to exhibit only local hormonal effects. There is an ongoing debate on whether LNG-IUDs can have side effects similar to systemic hormonal medication. Benign background parenchymal enhancement (BPE) in dynamic contrast–enhanced (DCE) MRI has been established as a sensitive marker of hormonal stimulation of the breast. We investigated the association between LNG-IUD use and BPE in breast MRI to further explore possible systemic effects of LNG-IUDs. Our hospital database was searched to identify premenopausal women without personal history of breast cancer, oophorectomy, and hormone replacement or antihormone therapy, who had undergone standardized DCE breast MRI at least twice, once with and without an LNG-IUD in place. To avoid confounding aging-related effects on BPE, half of included women had their first MRI without, the other half with, LNG-IUD in place. Degree of BPE was analyzed according to the ACR categories. Wilcoxon-matched-pairs signed-rank test was used to compare the distribution of ACR categories with vs. without LNG-IUD. Forty-eight women (mean age, 46 years) were included. In 24/48 women (50

Purpose:Application of MRF to evaluate the feasibility of 2D Dixon blurring-corrected MRF (2DDb-cMRF) to differentiate breast cancer (BC) from normal fibroglandular tissue (FGT). Methods:Prospective study on 14 patients with unilateral BC on 1.5 T system/axial T2w-TSE sequence, 2DDb-cMRF, B1 map, dynamic contrast-enhanced (DCE) T1-w GE-series. Mean T1 and T2 values and standard deviations were computed in the BC-/FGT-ROI on pre-/post-contrast MRF-maps and their differences were tested by two-tailed student t-test.Accuracy and repeatability of MRF were evaluated in a phantom experiment with gelatin with Primovist surrounded by fat.The T1 reduction between pre-/post-contrast MRF-maps was correlated to DCE signal enhancement in the last image post-contrast through the Pearson´s correlation coefficient (r) and for the phantom validation experiment through the Lin's concordance correlation coefficient (CCC).Visual evaluation of cancers on MRF-Maps was performed by rating each MRF-Map by 3 radiologists. Results:T1- and T2-MRF values of BC vs. FGT were for T1 and T2 pre-contrast respectively: 1147 ± 1 ms vs. 1052 ± 9 ms (p = 0.007) and 83 ± 1 ms vs. 73 ± 1 ms (p = 0.03); post-contrast respectively: 367.3 ± 121.5 ms vs. 690.3 ± 200.3 ms (p = 0.0005) and 76.9 ± 11.5 ms vs. 69.8 ± 15.2 ms (p = 0.12). r was positive (FGT r = 0.7; BC r = 0.6). CCC was 0.999 for T1 and 0.994 for T2. In the T1- and T2-MRF-Maps before contrast respectively (7,7,8)/14 and (5,9,8)/14 cancers were visible to the readers; afterwards, (11,12,12)/14 and (5,6,11)/14. Conclusions:MRF is promising for distinction between BC and FGT as well as for analyzing pre-/post-contrast T1 changes. However, its potential for differential diagnosis warrants further studies.

PURPOSE:To intra-individually compare patient comfort of spiral breast computed tomography (SBCT) versus digital mammography (DM). METHOD:This prospective IRB approved study included 79 patients undergoing both SBCT and DM for the assessment of BI-RADS 4 - 6 lesions. Following SBCT and DM patients answered a standardized questionnaire regarding "Overall patient comfort" and "Pain" on a 5-point Likert Scale. On the same Likert Scale, experienced radiologic technicians rated the workflow of the SBCT regarding patients' "Mobility", ease of patient "Positioning", patients' adherence to the examination ("Compliance") and expected image quality. Visibility of fibroglandular tissue in SBCT was independently rated by two breast radiologists on a 10-point Likert Scale. Subgroups stratified by menopausal status and body mass index (BMI) were analyzed. RESULTS:Patients reported significantly lower pain during SBCT (4.73 ± 0.57) compared to DM (4.09 ± 0.90; P < 0.01). This effect was independent from BMI. However, pain reduction by SBCT was most pronounced in premenopausal (SBCT vs. DM: 4.79 ± 0.50 vs. 3.89 ± 0.99) compared to postmenopausal patients (4.71 ± 0.77 vs. 4.20 ± 0.89). Overall patient comfort in premenopausal patients tended to be higher in SBCT compared to DM (P = 0.08). Radiologic technicians rated the SBCT procedure generally as positive (average: 4.62 ± 0.56). Coverage of fibroglandular tissue in SBCT was generally high (9.82 ± 0.43) and interrater agreement was good (κ = 0.77). CONCLUSIONS:Patients experience less pain during spiral breast computed tomography compared to DM, especially in premenopausal women. Imaging is feasible at a high level of anatomical breast coverage and without problems with the clinical workflow.

The primary objective of the study was to compare a spiral breast computed tomography system (SBCT) to digital breast tomosynthesis (DBT) for the detection of microcalcifications (MCs) in breast specimens. The secondary objective was to compare various reconstruction modes in SBCT. In total, 54 breast biopsy specimens were examined with mammography as a standard reference, with DBT, and with a dedicated SBCT containing a photon-counting detector. Three different reconstruction modes were applied for SBCT datasets (Recon1 = voxel size (0.15 mm)3, smooth kernel; Recon2 = voxel size (0.05 mm)3, smooth kernel; Recon3 = voxel size (0.05 mm)3, sharp kernel). Sensitivity and specificity of DBT and SBCT for the detection of suspicious MCs were analyzed, and the McNemar test was used for comparisons. Diagnostic confidence of the two readers (Likert Scale 1 = not confident; 5 = completely confident) was analyzed with ANOVA. Regarding detection of MCs, reader 1 had a higher sensitivity for DBT (94.3%) and Recon2 (94.9%) compared to Recon1 (88.5%; p < 0.05), while sensitivity for Recon3 was 92.4%. Respectively, reader 2 had a higher sensitivity for DBT (93.0%), Recon2 (92.4%), and Recon3 (93.0%) compared to Recon1 (86.0%; p < 0.05). Specificities ranged from 84.7–94.9% for both readers (p > 0.05). The diagnostic confidence of reader 1 was better with SBCT than with DBT (DBT 4.48 ± 0.88, Recon1 4.77 ± 0.66, Recon2 4.89 ± 0.44, and Recon3 4.75 ± 0.72; DBT vs. Recon1/2/3: p < 0.05), while reader 2 found no differences. Sensitivity and specificity for the detection of MCs in breast specimens is equal for DBT and SBCT when a small voxel size of (0.05 mm)3 is used with an equal or better diagnostic confidence for SBCT compared to DBT.

We conducted an in vivo trial to investigate the safety and efficacy of a newly developed system for the application of a combined therapy consisting of irreversible electroporation (IRE) and electrochemotherapy (IRECT) in the liver. The system is conceived as a single-needle multitined applicator with expandable electrodes that allow interstitial injection of fluids, e.g., chemotherapy. Experiments were conducted in ten domestic pigs. The applicator was placed in different liver lobes under CT guidance. In one lobe, the applicator was used for conventional IRE (1500 V, 120 pulses, pulse length 100 μs). In the other lobe, the same procedure was performed preceded by the injection of a doxorubicin mixture through the expandable electrodes (IRECT). Contrast-enhanced CT and MRI were performed on days 1, 3, and 7 after the procedure. Accordingly, three animals were sacrificed on days 1, 3, and 7 after the imaging and ablation volumes were evaluated histopathologically. Related t test was used to compare the groups. Technical success was achieved in 9/10 experiments. One animal deceased during the intervention because of ventricular fibrillation. Follow-up CT 1 and 3 days after intervention showed a significant (p < 0.05) difference in the ablation volumes of IRECT vs IRE, respectively, of 4.47 ± 1.78 ml vs 2.51 ± 0.93 ml and of 3.39 ± 1.05 vs 1.53 ± 0.78 ml. IRECT using the newly developed system proved to be effective and provided significantly larger ablation volumes compared with IRE alone. However, ECG triggering is a necessary prerequisite to allow a safe application of the system. • Working on the geometry of the IRE applicator in terms of expandable electrodes may overcome the current limitations of IRE resulting from the placement of multiple electrodes. • Efficacy of IRE ablations can be enhanced by the interstitial application of chemotherapy in the periphery of ablation areas.